Hims & Hers Health (HIMS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
29 May, 2026Mission and platform overview
Aims to help people feel great through better health by democratizing access to high-quality, personalized care using technology for a seamless customer experience.
Platform leverages data-driven insights, high-touch care, and best-in-class solutions to deliver tailored treatment plans and proactive engagement.
Leadership team includes experienced executives from major tech and healthcare organizations, supporting rapid scaling and innovation.
Market opportunity and expansion
Targets over 100 million potential consumers across specialties and regions, with significant untapped populations in key markets.
Recent and pending acquisitions (Zava, Livewell, Eucalyptus, YourBio) expand reach into Europe, Canada, Australia, and Japan, strengthening international presence.
International revenue grew nearly 10x year-over-year, with further growth expected as new markets are integrated.
Strategic growth levers
Value proposition strengthens with each new subscriber, driven by trusted brand, clinical excellence, and innovative technology.
Focus on deepening personalization, expanding into new specialties, elevating care precision, building strategic relationships, and global platform expansion.
Ecosystem provides value beyond medication, including lab diagnostics, habit tracking, and 24/7 support, fostering long-term customer relationships.
Latest events from Hims & Hers Health
- Q2 2026 revenue up 38–40% to $753M, but net loss $86M amid global expansion and higher costs.HIMS
Q2 2026 - Directors, auditor, and executive compensation were approved; Q&A to be answered post-meeting.HIMS
AGM 2026 - 2030 targets hinge on global expansion, specialty growth, and AI-driven platform leadership.HIMS
2026 Evercore Global TMT Conference - Q1 2026 revenue rose 4% to $608M, but net loss widened on restructuring and margin pressure.HIMS
Q1 2026 - Proxy covers director elections, auditor ratification, and executive pay, highlighting strong growth and governance.HIMS
Proxy filing - Votes sought for nine directors, auditor ratification, and executive pay at June 2026 meeting.HIMS
Proxy filing - 2025 revenue up 59% to $2.35B, with strong subscriber and specialty growth, and robust 2026 outlook.HIMS
Q4 2025 - Q2 revenue up 52% to $315.6M, net income $13.3M, 1.9M subscribers, and raised full-year guidance.HIMS
Q2 2024 - 2024 revenue up 69% to $1.5B, net income $126M, 2025 guidance set at $2.3–$2.4B revenue.HIMS
Q4 2024